PROS1 and infection: At study week 108 (10 months after the first infection), 12 hybrid-immune animals received a bivalent WA-1/BA.5 booster vaccine, composed of 2.5 μg NVX-CoV2373 (WA-1) and 2.5 μg NVX-CoV2540 (BA.5) S proteins.